文献速递临床试验与 GCP

瑞芬太尼与神经肌肉阻滞剂在误吸风险患者快速序贯插管中对无主要并发症成功插管的效果:一项随机临床试验

Effect of Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation on Successful Intubation Without Major Complications Among Patients at Risk of Aspiration: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

在法国15家医院手术室开展的 multicenter、随机、开放标签、非劣效性试验纳入1150例有误吸风险的成人,比较瑞芬太尼与神经肌肉阻滞剂在快速序贯插管中的效果。主要结局为首次尝试成功气管插管且无主要并发症,瑞芬太尼组66.1% vs 神经肌肉阻滞剂组71.6%,调整差异-6.1%(95%CI -11.6%至-0.5%),非劣效性检验P=.37,未达到非劣效性标准。

要点

  • 瑞芬太尼组首次插管无主要并发症66.1%,神经肌肉阻滞剂组71.6%,调整差异-6.1%。
  • 非劣效性检验P=.37,未达到预设7.0%的非劣效性界值,显示瑞芬太尼劣于神经肌肉阻滞剂。
  • 瑞芬太尼组血流动力学不稳定不良事件3.3% vs 神经肌肉阻滞剂组0.5%,调整差异2.8%。

核心结论

  • 在有误吸风险的成人快速序贯插管中,与神经肌肉阻滞剂相比,瑞芬太尼未达到首次尝试成功插管且无主要并发症的非劣效性标准。
  • 尽管瑞芬太尼在统计学上劣于神经肌肉阻滞剂,但效应估计的宽置信区间仍与不劣效性相容,限制了对差异临床相关性的结论。

研究设计与样本

  • 多中心、随机、开放标签、非劣效性试验,纳入1150例有误吸风险的成人(禁食<6小时、肠梗阻、近期创伤或严重胃食管反流),在法国15家医院手术室行气管插管,时间2019年10月至2021年4月,随访截至2021年5月15日。
  • 患者随机接受神经肌肉阻滞剂(琥珀胆碱或罗库溴铵1 mg/kg;n=575)或瑞芬太尼(3至4 μg/kg;n=575),在注射催眠药后立即给药。
  • 主要结局在全部随机患者(按随机分组人群)和所有接受分配治疗的合格患者(符合方案人群)中评估。

主要发现

  • 按随机分组人群,瑞芬太尼组575例中374例(66.1%)vs 神经肌肉阻滞剂组575例中408例(71.6%)首次尝试气管插管且无主要并发症,调整随机分层和中心后的组间差异-6.1%(95%CI -11.6%至-0.5%),非劣效性检验P=.37,显示劣效性。
  • 符合方案人群,瑞芬太尼组565例中374例(66.2%)vs 神经肌肉阻滞剂组565例中403例(71.3%)成功插管且无主要并发症,调整差异-5.7%(双侧95%CI -11.3%至-0.1%),非劣效性检验P=.32。
  • 瑞芬太尼组575例中19例(3.3%)vs 神经肌肉阻滞剂组575例中3例(0.5%)记录到血流动力学不稳定不良事件,调整差异2.8%(95%CI 1.2%-4.4%)。

关键数值与推荐

  • 主要结局为首次尝试成功气管插管且无主要并发症,主要并发症定义为消化内容物肺误吸、氧饱和度下降、主要血流动力学不稳定、持续性心律失常、心脏骤停和严重过敏反应。
  • 预设非劣效性界值为7.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出瑞芬太尼效应估计的宽置信区间仍与不劣效性相容,限制了对差异临床相关性的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is uncertain whether a rapid-onset opioid is noninferior to a rapid-onset neuromuscular blocker during rapid sequence intubation when used in conjunction with a hypnotic agent. OBJECTIVE: To determine whether remifentanil is noninferior to rapid-onset neuromuscular blockers for rapid sequence intubation. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, open-label, noninferiority trial among 1150 adults at risk of aspiration (fasting for <6 hours, bowel occlusion, recent trauma, or severe gastroesophageal reflux) who underwent tracheal intubation in the operating room at 15 hospitals in France from October 2019 to April 2021. Follow-up was completed on May 15, 2021. INTERVENTIONS: Patients were randomized to receive neuromuscular blockers (1 mg/kg of succinylcholine or rocuronium; n = 575) or remifentanil (3 to 4 μg/kg; n = 575) immediately after injection of a hypnotic. MAIN OUTCOMES AND MEASURES: The primary outcome was assessed in all randomized patients (as-randomized population) and in all eligible patients who received assigned treatment (per-protocol population). The primary outcome was successful tracheal intubation on the first attempt without major complications, defined as lung aspiration of digestive content, oxygen desaturation, major hemodynamic instability, sustained arrhythmia, cardiac arrest, and severe anaphylactic reaction. The prespecified noninferiority margin was 7.0%. RESULTS: Among 1150 randomized patients (mean age, 50.7 [SD, 17.4] years; 573 [50%] women), 1130 (98.3%) completed the trial. In the as-randomized population, tracheal intubation on the first attempt without major complications occurred in 374 of 575 patients (66.1%) in the remifentanil group and 408 of 575 (71.6%) in the neuromuscular blocker group (between-group difference adjusted for randomization strata and center, -6.1%; 95% CI, -11.6% to -0.5%; P = .37 for noninferiority), demonstrating inferiority. In the per-protocol population, 374 of 565 patients (66.2%) in the remifentanil group and 403 of 565 (71.3%) in the neuromuscular blocker group had successful intubation without major complications (adjusted difference, -5.7%; 2-sided 95% CI, -11.3% to -0.1%; P = .32 for noninferiority). An adverse event of hemodynamic instability was recorded in 19 of 575 patients (3.3%) with remifentanil and 3 of 575 (0.5%) with neuromuscular blockers (adjusted difference, 2.8%; 95% CI, 1.2%-4.4%). CONCLUSIONS AND RELEVANCE: Among adults at risk of aspiration during rapid sequence intubation in the operating room, remifentanil, compared with neuromuscular blockers, did not meet the criterion for noninferiority with regard to successful intubation on first attempt without major complications. Although remifentanil was statistically inferior to neuromuscular blockers, the wide confidence interval around the effect estimate remains compatible with noninferiority and limits conclusions about the clinical relevance of the difference. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03960801.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Grillot N, Lebuffe G, Huet O, et al. Effect of Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation on Successful Intubation Without Major Complications Among Patients at Risk of Aspiration: A Randomized Clinical Trial. JAMA. 2023. PMID: 36594947. doi:10.1001/jama.2022.23550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。